Loss of Fractalkine Signaling Affects CNS Tumor Growth via Microglia Interactions
Fractalkine 信号传导丧失通过小胶质细胞相互作用影响中枢神经系统肿瘤生长
基本信息
- 批准号:9271165
- 负责人:
- 金额:$ 4.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-12 至 2018-05-11
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Microglia is an immune cell type unique to the CNS that plays a pivotal role in immune surveillance, phagocytosis, and neuroinflammation1. Microglia resides in the brain parenchyma and help maintain the homeostatic immunosuppressive environment partially due to their expression of CX3CR1 receptor for which Fractalkine (FKN/CX3CL1) is the only known ligand. FKN is constitutively expressed by neurons and astrocytes leading to tonic inhibition of microglial activation2. However, we have found that in the presence of medulloblastoma (MB), FKN signaling is altered due to expression of FKN by tumor cells, and as such microglia play a major role as phagocytes displaying certain up-regulated cell surface makers consistent with an activated phenotype. This contrasts with other reports showing that infiltrating monocytes play the major role in neuronal destruction and promote a pro-inflammatory environment3, 4. Because the precise role of microglia in the tumor microenvironment has yet to be elucidated, further investigation is warranted. New and innovative approaches to cancer treatment are necessary to combat many cancer types, especially solid tumors. Available evidence now favors the view that physiological immune surveillance by members of the innate and adaptive immune systems play an essential role in suppressing tumor development in vivo, and that deficiency in this surveillance mechanism favors tumor development and metastasis formation5, 6. Additional challenges exist when solid tumors develop within the central nervous system (CNS), as immune surveillance within the CNS is further complicated by the presence of the blood brain barrier (BBB). MB is the most common malignant CNS neoplasm in the pediatric setting, accounting for 20% of pediatric CNS malignancies overall. It is a WHO-Grade IV primitive neuroectodermal tumor (PNET) that develops in the cerebellum and often invades into surrounding structures including the fourth ventricle and the brain stem7. While treatment modalities and, more importantly, management of post treatment cognitive monitoring have improved overall outcomes, surviving patients still suffer cognitive sequelae including but not limited to verbal ability, perceptual organization, social perception, and psychomotor skills8. Hence there is a need for new treatment options that avoid direct toxicities associated with CNS surgical, chemotherapeutic, and radiotherapy approaches. Understanding the mechanisms by which tumors escape detection and/or elimination by the innate and adaptive immune systems is imperative for developing new immune based therapeutics. FKN signaling may provide the key signal leading to microglia-mediated immune suppression within the CNS. Therefore, characterization of FKN signaling in the MB microenvironment will provide critical insight into the immunosuppressive capacity of tumors that will lead to more effective immunotherapeutic approaches.
描述(由应用程序提供):小胶质细胞是中枢神经系统独有的免疫胶体类型,在免疫监视,吞噬作用和神经炎症中起关键作用。小胶质细胞位于脑实质中,并有助于维持体内稳态免疫抑制环境,部分原因是它们的CX3CR1受体的表达,而fnavcr1受体(FKN/CX3CL1)是唯一已知的配体。 FKN始终由神经元和星形胶质细胞表达,从而导致小胶质细胞激活2。但是,我们发现在存在髓母细胞瘤(MB)的情况下,由于肿瘤细胞表达FKN,FKN信号传导改变了,因此小胶质细胞起着主要作用,因为吞噬细胞表现出与活性表型一致的某些上调的细胞表面制造商一致的上调细胞表面制造商。这与其他报道形成对比,表明浸润单核细胞在神经元破坏中起主要作用,并促进促炎环境3,4。由于小胶质细胞在肿瘤微环境中的精确作用尚未阐明,因此还保证了进一步的投资。为了打击许多癌症类型,尤其是实体瘤,必须采用新的和创新的癌症治疗方法。 Available evidence now favors the view that physical immunosurgery by members of the innate and adaptive immunosurgery systems play an essential role in suppressing tumor development in vivo, and that Deficiency in this surveillance mechanism favors tumor development and metastasis formation5, 6. Additional challenges exist when solid tumors develop within the central nervous system (CNS), as immunosurveillance within the CNS is further complicated by the presence of the血脑屏障(BBB)。 MB是儿科环境中最常见的恶性中枢神经系统肿瘤,占小儿中枢神经系统恶性肿瘤的20%。它是WHO级IV原始神经皮质肿瘤(PNET),它在小脑中发展,经常侵入包括第四脑室和脑茎7在内的周围结构。尽管治疗方式和更重要的是,治疗后认知监测的管理改善了总体结果,但生存患者仍然患有认知后遗症,包括但不限于言语能力,感知组织,社会感知和精神运动技能8。因此,需要新的治疗选择,以避免与中枢神经系统外科手术,化学治疗和放射疗法方法有关的直接毒性。了解先天和适应性免疫系统的肿瘤逃脱检测和/或消除的机制对于开发新的基于免疫的治疗至关重要。 FKN信号传导可能会提供关键信号,从而导致中枢神经系统内的小胶质细胞介导的免疫抑制。因此,MB微环境中FKN信号传导的表征将为肿瘤的免疫抑制能力提供关键的见解,这将导致更有效的免疫治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Rodney Dixon Doran...的其他基金
Loss of Fractalkine Signaling Affects CNS Tumor Growth via Microglia Interactions
Fractalkine 信号丢失通过小胶质细胞相互作用影响中枢神经系统肿瘤生长
- 批准号:90712969071296
- 财政年份:2015
- 资助金额:$ 4.9万$ 4.9万
- 项目类别:
相似海外基金
Immune recognition of Klebsiella pneumoniae O2v1 and O2v2 O-antigen subtypes
肺炎克雷伯菌 O2v1 和 O2v2 O 抗原亚型的免疫识别
- 批准号:1073904110739041
- 财政年份:2023
- 资助金额:$ 4.9万$ 4.9万
- 项目类别:
Antenatal Anxiety and Dyadic Immune Risk(ADIR Study)
产前焦虑和二元免疫风险(ADIR 研究)
- 批准号:1056186710561867
- 财政年份:2023
- 资助金额:$ 4.9万$ 4.9万
- 项目类别:
Early Onset Parkinson’s disease subtypes and pathogenic mechanisms
早发性帕金森病亚型及致病机制
- 批准号:1071964510719645
- 财政年份:2023
- 资助金额:$ 4.9万$ 4.9万
- 项目类别:
A microphysiological system with a synthetic hemoglobin, Blood Substitute, for mechanistic assessment of drug-induced liver injury
具有合成血红蛋白(血液替代品)的微生理系统,用于药物性肝损伤的机械评估
- 批准号:1038504810385048
- 财政年份:2022
- 资助金额:$ 4.9万$ 4.9万
- 项目类别:
A microphysiological system with a synthetic hemoglobin, Blood Substitute, for mechanistic assessment of drug-induced liver injury
具有合成血红蛋白(血液替代品)的微生理系统,用于药物性肝损伤的机械评估
- 批准号:1062529310625293
- 财政年份:2022
- 资助金额:$ 4.9万$ 4.9万
- 项目类别: